Products
Platform
Research
Market
Learn
Partner
Support
IPO

I

Indegene Share Price

538.1
+6.45 (1.21%)
INDGN • 22 Dec, 2025 | 03:29 PM
Buywith MTF at 3.33x leverage
The current prices are delayed, login or Open Demat Account for live prices.

Indegene Stock Performance

1W Return1.94
1Y Return-8.44
Today's Low526.55
Prev. Close531.65
Mkt Cap (Cr.)12,931.46
1M Return5.50
3Y Return0.00
52-Week High681.7
Open530.00
PE Ratio61.79
6M Return-6.76
Today's High544
52-Week Low499
Face Value2

Indegene Company background

Founded in: 1998
Indegene Limited was incorporated as Indegene Lifesystems Private Limited at Ahmedabad, Gujarat, as a Private Limited Company, dated October 16, 1998 at Ahmedabad. Subsequently, name of the Company was changed to Indegene Private Limited and a fresh Certificate of Incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. Thereafter, Company converted to a Public Company with change in name to Indegene Limited on November 17, 2022.The Company is a digitalfirst life sciences commercialization company, enabling biopharmaceutical, emerging biotech, and medical device companies to develop, launch, and scale the impact of their products with greater speed, precision, and efficiency. As a specialized company, it combine healthcare domain expertise, fitforpurpose technology, and an agile operating model to solve the most complex problems in the healthcare industry.Their Enterprise Commercial Solutions (ECS) involve assisting life sciences companies with their digital marketing operations. Omnichannel Activation solutions help life sciences companies leverage a digital first approach for optimizing the lastmile promotion of biopharmaceutical products and medical devices to HCPs across multiple channels. Under Enterprise Medical Solutions, the Company establish centers of excellence (CoEs) to consolidate large scale regulatory and medical operations for their clients.Apart from these, the Company offer Enterprise Clinical Solutions and consultancy services, which help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. It bring in their expertise in data management and analytics in helping biopharmaceutical companies seamlessly handle and analyze multiple sources of data during clinical trials and build a case for regulatory approvals.In 2016, the Company acquired Encima Group, Inc. in the United States, a company which provided marketing analytics and campaign execution solutions to several large life sciences companies. In 2019, it acquired a minority stake in DT Associates Research and Consulting Services Limited, a digital transformation and client experience consulting firm in UK, to expand their strategic consulting capabilities. In December 2020, it acquired a majority stake in DT Associates Limited.On 8 December, 2021 the Company has demerged its commercial software business pursuant to a Scheme of Arrangement for transfer of the Demerged Business to OT Services India Private Limited (Resulting Company), approved by the National Company Law Tribunal, Bengaluru Bench with Appointed Date, i.e., October 1, 2020, which became effective on December 30, 2021.The Company acquired Cult Health, a fullservice healthcare marketing agency for several life sciences brands, through its subsidiary, ILSL Holdings, Inc. on October 12, 2022.The Company launched Invisage, an AIenabled hybrid omnichannel sales and marketing platform in 2023. The Company made a public issue of 40,766,550 Equity Shares of face value of Rs 2 each by raising funds aggregating to Rs. 1842 Crore comprising a fresh issue of 16,833,818 Equity Shares aggregating to Rs. 760 Crore and 23,932,732 Equity Shares aggregating to Rs 1082 Crore through Offer for Sale in May, 2024.In 2024, the Company acquired a controlling stake in Trilogy Writing Consulting GmbH, a medical writing consultancy firm. It set up a new global delivery center in Hyderabad. In FY 2025, the Company launched a new center in Hyderabad to strengthen the business operations. In Europe, it launched a new entity in Spain and a new center in London. Indegenes Europebased clients became as a strategic hub for consulting and commercialization solutions and modernize their operations with an AIfirst approach. Further, the Company acquired MJL, a UKbased specialized healthcare advertising and communications agency. It launched Cortex, a fitforpurpose Generative AI platform for the life sciences industry.

Indegene Financial Highlights


For the full year FY2025–2026, revenue reached ₹2946.5 crore and profit touched at ₹406.7 crore.

Indegene Share Price Today


As of 23 Dec 2025, Indegene share price is ₹538.1. The stock opened at ₹530 and had closed at ₹531.6 the previous day. During today’s trading session, Indegene share price moved between ₹526.55 and ₹544.00, with an average price for the day of ₹535.27. Over the last 52 weeks, the stock has recorded a low of ₹499.00 and a high of ₹681.70. In terms of performance, Indegene share price has declined by 6.8% over the past six months and has declined by 9.71% over the last year.
Read More
View details of Market Depth

Indegene Fundamental

Market Cap (in crs)

12,931.46

Face Value

2

Turnover (in lacs)

1,351.74

Key Metrics

Qtr Change %
-8.3
Dividend yield 1yr %
Below industry Median
0.4

Indegene Key Financials

View more
Loading chart...
Indegene Quarterly Revenue
Indegene Yearly Revenue
Indegene Quarterly Net Profit/Loss
Indegene Yearly Net Profit/Loss

Indegene Result Highlights

  • Indegene Ltd reported a 5.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 16.3%.

  • Its expenses for the quarter were up by 9.5% QoQ and 18.3% YoY.

  • The net profit decreased 12.3% QoQ and increased 11.3% YoY.

  • The earnings per share (EPS) of Indegene Ltd stood at 4.23 during Q2 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Indegene Shareholding Pattern

Foreign Institutions
11.3%
Mutual Funds
3.1%
Domestic Institutions
6.9%
Public
81.7%

Indegene Technical Analysis

Moving Averages Analysis
538.1
Current Price
Bullish Moving Averages
11
Bearish Moving Averages
5
Day EMA5
533.50
Day EMA10
531.40
Day EMA12
530.80
Day EMA20
529.50
Day EMA26
529.60
Day EMA50
533.90
Day EMA100
544.50
Day EMA200
558.70
Delivery & Volume
Loading chart...

Day

59.80%

Week

55.10%

Month

58.00%

Delivery & Volume

536.22
Pivot
Resistance
First Resistance
545.88
Second Resistance
553.67
Third Resistance
563.33
Support
First Support
528.43
Second support
518.77
Third Support
510.98
Relative Strength Index
57.72
Money Flow Index
35.17
MACD
1.30
MACD Signal
-0.09
Average True Range
11.43
Average Directional Index
17.65
Rate of Change (21)
5.50
Rate of Change (125)
-6.01
Compare

Indegene Latest News

22 DEC 2025 | Monday
19 DEC 2025 | Friday
19 DEC 2025 | Friday

Please be aware that Indegene stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account